HD 1 - Tapestry Pharmaceuticals

Drug Profile

HD 1 - Tapestry Pharmaceuticals

Alternative Names: HD-1; Huntington's disease oligonucleotide therapy

Latest Information Update: 19 Nov 2007

Price : $50

At a glance

  • Originator Tapestry Pharmaceuticals
  • Class Oligonucleotides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 27 Apr 2006 No development reported - Preclinical for Huntington's disease in USA (unspecified route)
  • 11 May 2004 Napro Biotherapeutics is now called Tapestry Pharmaceuticals
  • 20 Jun 2003 Preclinical trials in Huntington's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top